This deep dive covers what 5+ years of GLP-1, growth hormone, and research peptide data actually shows from cardiovascular outcomes and cancer risk to muscle loss, bone health, and what clinical oversight looks like in practice
Our personalized approach helps identify contributing factors while providing treatments designed to support long-term hair health
The study examined safety parameters and metabolic biomarkers over a 12-week treatment period [2]
A 2-unit error on a 10-unit dose is a 20% difference
In the Phase 3 REDEFINE 1 trial, cagrilintide monotherapy achieved 11.8% average weight loss over 68 weekscomparable to semaglutide but with a notably lower incidence of nausea and vomiting, making it a potential option for patients who dont tolerate GLP-1 medications well
Overall, more high-quality research is needed to define the doses and clinical effects of this fascinating herb